Skip to main content
SpringerLink
Log in

Erdheim-Chester Disease

  • Chapter
  • First Online:
Histiocytic Disorders

Abstract

Erdheim-Chester disease (ECD) is a non-Langerhans cell histiocytosis and a rare disorder primarily affecting adults. Clinical manifestations vary widely, as does the severity of clinical phenotypes. The disease is defined by infiltration of involved tissues with CD1a (-) histiocytes, inflammation, and fibrosis, although the histopathologic profile of ECD lesions can vary between patients and affected organs. The identification of recurrent somatic alterations in mitogen-activating protein kinase (MAPK) pathway genes in ECD tissue, including the BRAF V600E mutation in ~50% of cases, has led to a reconceptualization of ECD as a myeloid neoplasm. Furthermore, these discoveries have opened the door to new therapeutic strategies holding promise for unprecedented efficacy in the treatment of ECD. Unanswered questions remain about how best to evaluate and implement these new therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer. 2005;45(3):256–64.

    Article  PubMed  Google Scholar 

  2. Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127:2672–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Chester W. Uber lipoidgranulomatose. Virchows Arch Pathol Anat. 1930;279:561–602.

    Article  Google Scholar 

  4. Haroche J, Cohen-Aubart F, Charlotte F, Maksud P, Grenier PA, Cluzel P, et al. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm. Expert Rev Clin Immunol. 2015;11(9):1033–42.

    Article  CAS  PubMed  Google Scholar 

  5. Haroche J, Charlotte F, Arnaud L, von Deimling A, Helias-Rodzewicz Z, Hervier B, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700–3.

    Article  CAS  PubMed  Google Scholar 

  6. Emile JF, Charlotte F, Amoura Z, Haroche J. BRAF mutations in Erdheim-Chester disease. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2013;31(3):398.

    Article  Google Scholar 

  7. Blombery P, Wong SQ, Lade S, Prince HM. Erdheim-Chester disease harboring the BRAF V600E mutation. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2012;30(32):e331–2.

    Article  Google Scholar 

  8. Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154–65.

    Article  CAS  PubMed  Google Scholar 

  9. Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124(4):483–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sohn MH, Kim MW, Kang YH, Jeong HJ. Tc-99m MDP bone and Ga-67 citrate scintigraphy of Erdheim-Chester disease in a child. Clin Nucl Med. 2006;31(2):90–2.

    Article  PubMed  Google Scholar 

  11. Joo CU, Go YS, Kim IH, Kim CS, Lee SY. Erdheim-Chester disease in a child with MR imaging showing regression of marrow changes. Skelet Radiol. 2005;34(5):299–302.

    Article  Google Scholar 

  12. Tran TA, Pariente D, Lecron JC, Delwail A, Taoufik Y, Meinzer U. Treatment of pediatric Erdheim-Chester disease with interleukin-1-targeting drugs. Arthritis Rheum. 2011;63(12):4031–2.

    Article  CAS  PubMed  Google Scholar 

  13. Song SY, Lee SW, Ryu KH, Sung SH. Erdheim-Chester disease with multisystem involvement in a 4-year-old. Pediatr Radiol. 2012;42(5):632–5.

    Article  PubMed  Google Scholar 

  14. Tran TA, Fabre M, Pariente D, Craiu I, Haroche J, Charlotte F, et al. Erdheim-Chester disease in childhood: a challenging diagnosis and treatment. J Pediatr Hematol Oncol. 2009;31(10):782–6.

    Article  PubMed  Google Scholar 

  15. Clerico A, Ragni G, Cappelli C, Schiavetti A, Gonfiantini M, Uccini S. Erdheim-Chester disease in a child. Med Pediatr Oncol. 2003;41(6):575–7.

    Article  PubMed  Google Scholar 

  16. Alimohamadi M, Hartmann C, Paterno V, Samii M. Erdheim-Chester disease mimicking an intracranial trigeminal schwannoma: case report. J Neurosurg Pediatr. 2015;15(5):493–8.

    Article  PubMed  Google Scholar 

  17. Kim S, Lee M, Shin HJ, Lee J, Suh YL. Coexistence of intracranial Langerhans cell histiocytosis and Erdheim-Chester disease in a pediatric patient: a case report. Childs Nerv Syst (ChNS: Official Journal of the International Society for Pediatric Neurosurgery). 2016;32(5):893–6.

    Article  Google Scholar 

  18. Krishna VV, James TE, Chang KT, Yen SS. Erdheim-Chester disease with rare radiological features in a 14-year old girl with pre-B acute lymphocytic leukemia and diabetes mellitus. J Radiol Case Rep. 2014;8(8):7–15.

    PubMed  PubMed Central  Google Scholar 

  19. Haroche J, Arnaud L, Cohen-Aubart F, Hervier B, Charlotte F, Emile JF, et al. Erdheim-Chester disease. Rheum Dis Clin N Am. 2013;39(2):299–311.

    Article  Google Scholar 

  20. Furmanczyk PS, Bruckner JD, Gillespy T 3rd, Rubin BP. An unusual case of Erdheim-Chester disease with features of Langerhans cell histiocytosis. Skelet Radiol. 2007;36(9):885–9.

    Article  Google Scholar 

  21. Tsai JW, Tsou JH, Hung LY, Wu HB, Chang KC. Combined Erdheim-Chester disease and Langerhans cell histiocytosis of skin are both monoclonal: a rare case with human androgen-receptor gene analysis. J Am Acad Dermatol. 2010;63(2):284–91.

    Article  PubMed  Google Scholar 

  22. Naruse H, Shoda H, Okamoto A, Oka T, Yamamoto K. A case of Osteoarthropathy due to Erdheim-Chester disease with overlapping Langerhans' cell infiltration. Intern Med. 2010;49(12):1225–8.

    Article  PubMed  Google Scholar 

  23. Caoduro C, Ungureanu CM, Rudenko B, Angoue O, Blagosklonov O, Paycha F, et al. 18F-fluoride PET/CT aspect of an unusual case of Erdheim-Chester disease with histologic features of Langerhans cell histiocytosis. Clin Nucl Med. 2013;38(7):541–2.

    Article  PubMed  Google Scholar 

  24. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: WHO Press; 2008.

    Google Scholar 

  25. Durham BH, Diamond EL, Abdel-Wahab O. Histiocytic neoplasms in the era of personalized genomic medicine. Curr Opin Hematol. 2016;23(4):416–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Diamond EL, Abdel-Wahab O, Pentsova E, Borsu L, Chiu A, Teruya-Feldstein J, et al. Detection of an NRAS mutation in Erdheim-Chester disease. Blood. 2013;122(6):1089–91.

    Article  CAS  PubMed  Google Scholar 

  27. Aitken SJ, Presneau N, Tirabosco R, Amary MF, O’Donnell P, Flanagan AM. An NRAS mutation in a case of Erdheim-Chester disease. Histopathology. 2015;66(2):316–9.

    Article  PubMed  Google Scholar 

  28. Emile JF, Diamond EL, Helias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014;124(19):3016–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Gianfreda D, Nicastro M, Galetti M, Alberici F, Corradi D, Becchi G, et al. Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. Blood. 2015;126(10):1163–71.

    Article  CAS  PubMed  Google Scholar 

  30. Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, et al. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov. 2015;5(1):64–71.

    Article  CAS  PubMed  Google Scholar 

  31. Diamond EL, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Brody L, et al. Anakinra as efficacious therapy for two cases of intracranial Erdheim-Chester disease. Blood. 2016;128:1896–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Nelson DS, Quispel W, Badalian-Very G, van Halteren AG, van den Bos C, Bovee JV, et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood. 2014;123(20):3152–5.

    Article  CAS  PubMed  Google Scholar 

  33. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009;15(9):3143–9.

    Article  CAS  PubMed  Google Scholar 

  34. Takeuchi T, Sato M, Sonomura T, Itakura T. Erdheim-Chester disease associated with intramedullary spinal cord lesion. Br J Radiol. 2012;85(1011):e62–4.

    Article  CAS  PubMed  Google Scholar 

  35. Mano H. ALKoma: a cancer subtype with a shared target. Cancer Discov. 2012;2(6):495–502.

    Article  CAS  PubMed  Google Scholar 

  36. Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014;5:3116.

    PubMed  PubMed Central  Google Scholar 

  37. Berres ML, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X? Br J Haematol. 2015;169(1):3–13.

    Article  PubMed  Google Scholar 

  38. Badalian-Very G. A common progenitor cell in LCH and ECD. Blood. 2014;124(7):991–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Allen CE, Parsons DW. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders. Hematology Am Soc Hematol Educ Program. 2015;2015:559–64.

    PubMed  Google Scholar 

  40. Collin M, Bigley V, McClain KL, Allen CE. Cell(s) of origin of langerhans cell histiocytosis. Hematol Oncol Clin North Am. 2015;29(5):825–38.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Allen CE, Li L, Peters TL, Leung HC, Yu A, Man TK, et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 2010;184(8):4557–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211:669–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014;124(19):3007–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Hervier B, Haroche J, Arnaud L, Charlotte F, Donadieu J, Neel A, et al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood. 2014;124(7):1119–26.

    Article  CAS  PubMed  Google Scholar 

  45. Haroche J, Abla O. Uncommon histiocytic disorders: Rosai-Dorfman, juvenile xanthogranuloma, and Erdheim-Chester disease. Hematology Am Soc Hematol Educ Program. 2015;2015:571–8.

    PubMed  Google Scholar 

  46. Breuil V, Brocq O, Pellegrino C, Grimaud A, Euller-Ziegler L. Erdheim-Chester disease: typical radiological bone features for a rare xanthogranulomatosis. Ann Rheum Dis. 2002;61(3):199–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Garcia-Gomez FJ, Acevedo-Banez I, Martinez-Castillo R, Tirado-Hospital JL, Cuenca-Cuenca JI, Pachon-Garrudo VM, et al. The role of 18FDG, 18FDOPA PET/CT and 99mTc bone scintigraphy imaging in Erdheim-Chester disease. Eur J Radiol. 2015;84(8):1586–92.

    Article  CAS  PubMed  Google Scholar 

  48. Garcia-Gomez FJ, Cambil-Molina T, Rios-Martin JJ, de la Riva-Perez PA, Calvo-Moron C, Castro-Montano J. Bone scintigraphy as cornerstone in the diagnosis of Erdheim-Chester disease. Rev Esp Med Nucl Imagen Mol. 2016;35(3):193–6.

    CAS  PubMed  Google Scholar 

  49. Gotthardt M, Welcke U, Brandt D, Tontsch D, Barth PJ, Schaefer J, et al. The role of bone scintigraphy in patients with Erdheim-Chester disease. Clin Nucl Med. 2000;25(6):414–20.

    Article  CAS  PubMed  Google Scholar 

  50. Wilejto M, Abla O. Langerhans cell histiocytosis and Erdheim-Chester disease. Curr Opin Rheumatol. 2012;24(1):90–6.

    Article  CAS  PubMed  Google Scholar 

  51. Allmendinger AM, Krauthamer AV, Spektor V, Aziz MS, Zablow B. Atypical spine involvement of Erdheim-Chester disease in an elderly male. J Neurosurg Spine. 2010;12(3):257–60.

    Article  PubMed  Google Scholar 

  52. Caglar E, Aktas E, Aribas BK, Sahin B, Terzi A. Erdheim-Chester disease in thoracic spine: a rare case of compression fracture. Spine J (Official Journal of the North American Spine Society). 2016;16(4):e257–8.

    Article  Google Scholar 

  53. Klieger MR, Schultz E, Elkowitz DE, Arlen M, Hajdu SI. Erdheim-Chester disease: a unique presentation with multiple osteolytic lesions of the spine and pelvis that spared the appendicular skeleton. AJR Am J Roentgenol. 2002;178(2):429–32.

    Article  PubMed  Google Scholar 

  54. Nagatsuka H, Han PP, Taguchi K, Tsujigiwa H, Gunduz M, Fukunaga J, et al. Erdheim-Chester disease in a child presenting with multiple jaw lesions. J oral Pathol Med (Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology). 2005;34(7):420–2.

    Article  Google Scholar 

  55. Petrikowski CG, McGaw WT. Erdheim-Chester disease of the jaws: literature review and case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90(3):389–98.

    Article  CAS  PubMed  Google Scholar 

  56. Valdez IH, Katz RW, Travis WD. Premature alveolar bone loss in Erdheim-Chester disease. Oral Surg Oral Med Oral Pathol. 1990;70(3):294–6.

    Article  CAS  PubMed  Google Scholar 

  57. Blomstrand L, Thor A, Hagberg H. Erdheim-Chester disease presenting as periodontal disease: experience of treatment with cladribine, interferon-a, local radiotherapy and anakinra. Acta Oncol. 2016;55(2):248–50.

    Article  PubMed  Google Scholar 

  58. Fink MG, Levinson DJ, Brown NL, Sreekanth S, Sobel GW. Erdheim-Chester disease. Case report with autopsy findings. Arch Pathol Lab Med. 1991;115(6):619–23.

    CAS  PubMed  Google Scholar 

  59. Loeffler AG, Memoli VA. Myocardial involvement in Erdheim-Chester disease. Arch Pathol Lab Med. 2004;128(6):682–5.

    PubMed  Google Scholar 

  60. Serratrice J, Granel B, De Roux C, Pellissier JF, Swiader L, Bartoli JM, et al. “Coated aorta”: a new sign of Erdheim-Chester disease. J Rheumatol. 2000;27(6):1550–3.

    CAS  PubMed  Google Scholar 

  61. Rodriguez Sanchez D, Saura Espin D, Bas BA. Erdheim-Chester syndrome with Periaortitis. Revista espanola de cardiologia. 2016;69(1):72.

    Article  PubMed  Google Scholar 

  62. Windisch C, Petersen I, Schulz B, Winkens T, Lopatta E, Oelzner P, et al. Erdheim-Chester disease with vascular involvement mimics large vessel vasculitis. Postgrad Med J. 2016;92:687–8.

    Article  Google Scholar 

  63. Raptis DA, Raptis CA, Jokerst C, Bhalla S. Erdheim-Chester disease with interatrial septum involvement. J Thorac Imaging. 2012;27(5):W105–7.

    Article  PubMed  Google Scholar 

  64. de Miguel CJ, Aguilera Del Hoyo LF, Garcia Del Salto L, Cueva Perez E, Casado Cerrada J, Nieto Llanos S, et al. Case 224: cardiac involvement in Erdheim-Chester disease. Radiology. 2015;277(3):916–21.

    Article  Google Scholar 

  65. Arnaud L, Hervier B, Neel A, Hamidou MA, Kahn JE, Wechsler B, et al. CNS involvement and treatment with interferon- are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117(10):2778–82.

    Article  CAS  PubMed  Google Scholar 

  66. Hwang BY, Liu A, Kern J, Goodwin CR, Wolinsky JP, Desai A. Epidural spinal involvement of Erdheim-Chester disease causing myelopathy. J Clin Neurosci (Official Journal of the Neurosurgical Society of Australasia). 2015;22(9):1532–6.

    Article  Google Scholar 

  67. Albayram S, Kizilkilic O, Zulfikar Z, Islak C, Kocer N. Spinal dural involvement in Erdheim-Chester disease: MRI findings. Neuroradiology. 2002;44(12):1004–7.

    Article  PubMed  Google Scholar 

  68. Querat C, Thai-Van H, Durand DV, Cotton F, Gallego S, Truy E. Hearing rehabilitation with a binaural cochlear implant in a patient with Erdheim-Chester disease. Cochlear Implants Int. 2015;16(5):295–300.

    Article  PubMed  Google Scholar 

  69. Pego-Reigosa R, Branas-Fernandez F, Martinez-Vazquez F, Rivas-Bande MJ, Sanjuanbenito L, Garcia-Villanueva M, et al. Erdheim-Chester disease with spinal cord manifestations. Eur Neurol. 2000;43(4):242–4.

    Article  CAS  PubMed  Google Scholar 

  70. Lalitha P, Reddy M, Reddy KJ. Extensive intracranial juvenile xanthogranulomas. AJNR Am J Neuroradiol. 2011;32(7):E132–3.

    Article  CAS  PubMed  Google Scholar 

  71. Sagnier S, Debruxelles S, Lepreux S, Sibon I. Erdheim-Chester disease: an unusual cause of intracranial Vasculitis and progressive leukoencephalopathy. J stroke Cerebrovasc Dis (The Official Journal of National Stroke Association). 2016;25(5):e63–5.

    Article  Google Scholar 

  72. Grois N, Fahrner B, Arceci RJ, Henter JI, McClain K, Lassmann H, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010;156(6):873–81, 81 e1.

    Google Scholar 

  73. Diamond EL. Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease. Orphanet J Rare Dis. 2016;11(1):109.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Merritt H, Pfeiffer ML, Richani K, Phillips ME. Erdheim-Chester disease with orbital involvement: case report and ophthalmic literature review. Orbit. 2016;35(4):221–6.

    Article  PubMed  Google Scholar 

  75. Karcioglu ZA, Sharara N, Boles TL, Nasr AM. Orbital xanthogranuloma: clinical and morphologic features in eight patients. Ophthal Plast Reconstr Surg. 2003;19(5):372–81.

    Article  PubMed  Google Scholar 

  76. Abdellatief A, Mason CM, Ytterberg SR, Boorjian SA, Salomao DR, Pulido J. Choroidal involvement in Erdheim-Chester disease. Ophthalmic Surg Lasers Imaging Retina. 2015;46(6):674–6.

    Article  PubMed  Google Scholar 

  77. Courtillot C, Laugier Robiolle S, Cohen Aubart F, Leban M, Renard-Penna R, Drier A, et al. Endocrine manifestations in a monocentric cohort of 64 patients with Erdheim-Chester disease. J Clin Endocrinol Metab. 2016;101(1):305–13.

    Article  CAS  PubMed  Google Scholar 

  78. Sedrak P, Ketonen L, Hou P, Guha-Thakurta N, Williams MD, Kurzrock R, et al. Erdheim-Chester disease of the central nervous system: new manifestations of a rare disease. Am J Neuroradiol. 2011;32(11):2126–31.

    Article  CAS  PubMed  Google Scholar 

  79. Mukherjee A, Dhull VS, Karunanithi S, Sharma P, Durgapal P, Kumar R. Pineal gland involvement in Erdheim-Chester disease detected on (18)F-FDG PET-CT imaging: a case report and review of literature. Clin Imaging. 2014;38(3):367–71.

    Article  PubMed  Google Scholar 

  80. Yelfimov DA, Lightner DJ, Tollefson MK. Urologic manifestations of Erdheim-Chester disease. Urology. 2014;84(1):218–21.

    Article  PubMed  Google Scholar 

  81. Chasset F, Barete S, Charlotte F, Cohen-Aubart F, Arnaud L, Le Pelletier F, et al. Cutaneous manifestations of Erdheim-Chester disease (ECD): clinical, pathological, and molecular features in a monocentric series of 40 patients. J Am Acad Dermatol. 2016;74(3):513–20.

    Article  PubMed  Google Scholar 

  82. Caputo R, Marzano AV, Passoni E, Berti E. Unusual variants of non-Langerhans cell histiocytoses. J Am Acad Dermatol. 2007;57(6):1031–45.

    Article  PubMed  Google Scholar 

  83. Barnes PJ, Foyle A, Hache KA, Langley RG, Burrell S, Juskevicius R. Erdheim-Chester disease of the breast: a case report and review of the literature. Breast J. 2005;11(6):462–7.

    Article  PubMed  Google Scholar 

  84. Provenzano E, Barter SJ, Wright PA, Forouhi P, Allibone R, Ellis IO. Erdheim-chester disease presenting as bilateral clinically malignant breast masses. Am J Surg Pathol. 2010;34(4):584–8.

    Article  PubMed  Google Scholar 

  85. Ferrozzi F, Bova D, Tognini G, Zuccoli G. Pseudotumoral bilateral involvement of the breast in Erdheim-Chester disease: CT appearance. J Comput Assist Tomogr. 2000;24(2):281–3.

    Article  CAS  PubMed  Google Scholar 

  86. Sheu SY, Wenzel RR, Kersting C, Merten R, Otterbach F, Schmid KW. Erdheim-Chester disease: case report with multisystemic manifestations including testes, thyroid, and lymph nodes, and a review of literature. J Clin Pathol. 2004;57(11):1225–8.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Yamamoto T, Mizuno K. Erdheim-Chester disease with intramuscular lipogranuloma. Skelet Radiol. 2000;29(4):227–30.

    Article  CAS  Google Scholar 

  88. Taguchi S, Kishida Y, Tamura K, Nose Y, Sato T, Ishikawa A, et al. Intrapelvic bulky tumor as an unusual presentation of Erdheim-Chester disease. Internal Med (Tokyo, Japan). 2015;54(24):3241–5.

    Article  CAS  Google Scholar 

  89. Nadjiri J, Woertler K, Specht K, Harrasser N, Toepfer A. Erdheim-Chester disease with bilateral Achilles tendon involvement. Skelet Radiol. 2016:1–6.

    Google Scholar 

  90. Pan A, Doyle T, Schlup M, Lubcke R, Schultz M. Unusual manifestation of Erdheim-Chester disease. BMC Gastroenterol. 2011;11:77.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Ivan D, Neto A, Lemos L, Gupta A. Erdheim-Chester disease: a unique presentation with liver involvement and vertebral osteolytic lesions. Arch Pathol Lab Med. 2003;127(8):e337–9.

    PubMed  Google Scholar 

  92. Moore FO, Berne JD, Fox AD. Mesenteric panniculitis and Erdheim-Chester disease: xanthogranulomatous diseases confused with malignancy. J Am Coll Surg. 2007;204(2):326–7.

    Article  PubMed  Google Scholar 

  93. Namwongprom S, Nunez R, Kim EE, Macapinlac HA. Tc-99m MDP bone scintigraphy and positron emission tomography/computed tomography (PET/CT) imaging in Erdheim-Chester disease. Clin Nucl Med. 2007;32(1):35–8.

    Article  PubMed  Google Scholar 

  94. Lin E. FDG PET/CT for biopsy guidance in Erdheim-Chester disease. Clin Nucl Med. 2007;32(11):860–1.

    Article  PubMed  Google Scholar 

  95. Stenova E, Steno B, Povinec P, Ondrias F, Rampalova J. FDG-PET in the Erdheim-Chester disease: its diagnostic and follow-up role. Rheumatol Int. 2012;32(3):675–8.

    Article  PubMed  Google Scholar 

  96. Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495–500.

    Article  CAS  PubMed  Google Scholar 

  97. Haroche J, Cohen-Aubart F, Emile JF, Maksud P, Drier A, Toledano D, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2015;33(5):411–8.

    Article  CAS  Google Scholar 

  98. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Cohen-Aubart F, Emile JF, Maksud P, Galanaud D, Idbaih A, Chauvet D, et al. Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease. Neurology. 2014;83(14):1294–6.

    Article  PubMed  Google Scholar 

  100. Euskirchen P, Haroche J, Emile JF, Buchert R, Vandersee S, Meisel A. Complete remission of critical neurohistiocytosis by vemurafenib. Neurol Neuroimmunol Neuroinflamm. 2015;2(2):e78.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Franconieri F, Martin-Silva N, de Boysson H, Galateau-Salle F, Emile JF, Bienvenu B, et al. Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: towards the paradigm of combined targeting and immune therapies. Acta Oncol. 2016;55(7)930–2.

    Google Scholar 

  102. Tzoulis C, Schwarzlmuller T, Gjerde IO, Softeland E, Neckelmann G, Biermann M, et al. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. BMC Res Notes. 2015;8:171.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Borys D, Nystrom L, Song A, Lomasney LM. Erdheim Chester disease with appendicular skeletal, renal and pleural involvement responding to Zelboraf (BRAF inhibitor) treatment: case report. Skelet Radiol. 2016;45(10):1397–402.

    Article  Google Scholar 

  104. Braiteh F, Boxrud C, Esmaeli B, Kurzrock R. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood. 2005;106(9):2992–4.

    Article  CAS  PubMed  Google Scholar 

  105. Suzuki HI, Hosoya N, Miyagawa K, Ota S, Nakashima H, Makita N, et al. Erdheim-Chester disease: multisystem involvement and management with interferon-alpha. Leuk Res. 2010;34(1):e21–4.

    Article  CAS  PubMed  Google Scholar 

  106. Haroche J, Amoura Z, Trad SG, Wechsler B, Cluzel P, Grenier PA, et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum. 2006;54(10):3330–6.

    Article  CAS  PubMed  Google Scholar 

  107. Hervier B, Arnaud L, Charlotte F, Wechsler B, Piette JC, Amoura Z, et al. Treatment of Erdheim-Chester disease with long-term high-dose interferon-alpha. Semin Arthritis Rheum. 2012;41(6):907–13.

    Article  CAS  PubMed  Google Scholar 

  108. Esmaeli B, Ahmadi A, Tang R, Schiffman J, Kurzrock R. Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease. Am J Ophthalmol. 2001;132(6):945–7.

    Article  CAS  PubMed  Google Scholar 

  109. Arnaud L, Hervier B, Neel A, Hamidou MA, Kahn JE, Wechsler B, et al. CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117(10):2778–82.

    Article  CAS  PubMed  Google Scholar 

  110. Aouba A, Georgin-Lavialle S, Pagnoux C, Martin Silva N, Renand A, Galateau-Salle F, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 2010;116(20):4070–6.

    Article  CAS  PubMed  Google Scholar 

  111. Aubert O, Aouba A, Deshayes S, Georgin-Lavialle S, Rieu P, Hermine O. Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra. Joint Bone Spine. 2013;80(2):206–7.

    Article  CAS  PubMed  Google Scholar 

  112. Darstein F, Kirschey S, Heckl S, Rahman F, Schwarting A, Schuchmann M, et al. Successful treatment of Erdheim-Chester disease with combination of interleukin-1-targeting drugs and high-dose glucocorticoids. Intern Med J. 2014;44(1):90–2.

    Article  CAS  PubMed  Google Scholar 

  113. Sevcikova S, Kubiczkova L, Sedlarikova L, Rihova L, Kryukov F, Szturz P, et al. Impact of anakinra treatment on cytokine and lymphocytes/ monocytes profile of an Erdheim-Chester patient. Klin Onkol. 2014;27(4):276–82.

    Article  CAS  PubMed  Google Scholar 

  114. Podesta MA, Graziani G, Reggiani F, Buemi M, Badalamenti S, Ponticelli C. Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra. Kidney Res Clin Pract. 2014;33(3):165–7.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Courcoul A, Vignot E, Chapurlat R. Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein. Joint Bone Spine. 2014;81(2):175–7.

    Article  PubMed  Google Scholar 

  116. Killu AM, Liang JJ, Jaffe AS. Erdheim-Chester disease with cardiac involvement successfully treated with anakinra. Int J Cardiol. 2013;167(5):e115–7.

    Article  PubMed  Google Scholar 

  117. Cohen-Aubart F, Maksud P, Saadoun D, Drier A, Charlotte F, Cluzel P, et al. Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. Blood. 2016;127(11):1509–12.

    Article  CAS  PubMed  Google Scholar 

  118. Haroche J, Amoura Z, Charlotte F, Salvatierra J, Wechsler B, Graux C, et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood. 2008;111(11):5413–5.

    Article  CAS  PubMed  Google Scholar 

  119. Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol. 2010;28(31):e633–6.

    Article  PubMed  Google Scholar 

  120. Dagna L, Corti A, Langheim S, Guglielmi B, De Cobelli F, Doglioni C, et al. Tumor necrosis factor alpha as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol (Official Journal of the American Society of Clinical Oncology). 2012;30(28):e286–90.

    Article  Google Scholar 

  121. Ferrero E, Belloni D, Corti A, Doglioni C, Dagna L, Ferrarini M. TNF-alpha in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. Rheumatology. 2014;53(1):198–200.

    Google Scholar 

  122. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007;89(6–7):884–93.

    Article  CAS  PubMed  Google Scholar 

  123. Tran TA, Pariente D, Guitton C, Delwail A, Barat-Houari M, Meinzer U. Treatment of Erdheim-Chester disease with canakinumab. Rheumatology. 2014;53(12):2312–4.

    Article  PubMed  Google Scholar 

  124. Jendro MC, Zeidler H, Rosenthal H, Haller H, Schwarz A. Improvement of Erdheim-Chester disease in two patients by sequential treatment with vinblastine and mycophenolate mofetil. Clin Rheumatol. 2004;23(1):52–6.

    Article  PubMed  Google Scholar 

  125. Broccoli A, Stefoni V, Faccioli L, Agostinelli C, Spinardi L, Pastore Trossello M, et al. Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. Rheumatol Int. 2012;32(7):2209–13.

    Article  PubMed  Google Scholar 

  126. Boissel N, Wechsler B, Leblond V. Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Intern Med. 2001;135(9):844–5.

    Article  CAS  PubMed  Google Scholar 

  127. Bourke SC, Nicholson AG, Gibson GJ. Erdheim-Chester disease: pulmonary infiltration responding to cyclophosphamide and prednisolone. Thorax. 2003;58(11):1004–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Yano S, Kobayashi K, Kato K, Tokuda Y, Ikeda T, Takeyama H. A case of Erdheim-Chester disease effectively treated by cyclophosphamide and prednisolone. Nihon Kokyuki Gakkai Zasshi. 2007;45(1):43–8.

    PubMed  Google Scholar 

  129. Gaspar N, Boudou P, Haroche J, Wechsler B, Van Den Neste E, Hoang-Xuan K, et al. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for adult histiocytic disorders with central nervous system involvement. Haematologica. 2006;91(8):1121–5.

    CAS  PubMed  Google Scholar 

  130. Ho P, Smith C. High-dose methotrexate for the treatment of relapsed central nervous system erdheim-chester disease. Case Rep Hematol. 2014;53(1):198–200.

    Google Scholar 

  131. Jeon IS, Lee SS, Lee MK. Chemotherapy and interferon-alpha treatment of Erdheim-Chester disease. Pediatr Blood Cancer. 2010;55(4):745–7.

    Article  PubMed  Google Scholar 

  132. Myra C, Sloper L, Tighe PJ, McIntosh RS, Stevens SE, Gregson RH, et al. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol. 2004;88(6):844–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Adam Z, Sprlakova A, Rehak Z, Koukalova R, Szturz P, Krejci M, et al. Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide. Klin Onkol. 2011;24(5):367–81.

    CAS  PubMed  Google Scholar 

  134. Azadeh N, Tazelaar HD, Gotway MB, Mookadam F, Fonseca R. Erdheim Chester disease treated successfully with cladribine. Respiratory Med Case Rep. 2016;18:37–40.

    Article  Google Scholar 

  135. Mascalchi M, Nencini P, Nistri M, Sarti C, Santoni R. Failure of radiation therapy for brain involvement in Erdheim Chester disease. J Neuro-Oncol. 2002;59(2):169–72.

    Article  Google Scholar 

  136. Miller RC, Villà S, Kamer S, Pasquier D, Poortmans P, Micke O, et al. Palliative treatment of Erdheim–Chester disease with radiotherapy: a rare cancer network study. Radiother Oncol. 2006;80(3):323–6.

    Article  PubMed  Google Scholar 

  137. Haroche J, Amoura Z. mTOR: a new target in Erdheim-Chester disease? Blood. 2015;126(10):1151–2.

    Article  CAS  PubMed  Google Scholar 

  138. Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med. 2012;367(24):2316–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Montella L, Insabato L, Palmieri G. Imatinib mesylate for cerebral Langerhans'-cell histiocytosis. N Engl J Med. 2004;351(10):1034–5.

    Article  CAS  PubMed  Google Scholar 

  140. Utikal J, Ugurel S, Kurzen H, Erben P, Reiter A, Hochhaus A, et al. Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. Arch Dermatol. 2007;143(6):736–40.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Eli L. Diamond MD & Benjamin H. Durham

Authors
  1. Eli L. Diamond MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benjamin H. Durham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eli L. Diamond MD .

Editor information

Editors and Affiliations

  1. University of Toronto, The Hospital for Sick Children, Toronto, Ontario, Canada

    Oussama Abla

  2. Pediatric Hematology and Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany

    Gritta Janka

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Diamond, E.L., Durham, B.H. (2018). Erdheim-Chester Disease. In: Abla, O., Janka, G. (eds) Histiocytic Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-59632-7_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-59632-7_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-59631-0

  • Online ISBN: 978-3-319-59632-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation